Neuralstem rises after announcing start of stem cell trial


The University of Michigan has treated the first two patients in a Phase II trial testing the effectiveness of Neuralstem's (CUR +5.9%) NSI-566 neural stem cells in treating ALS (Lou Gehrig's disease). (PR)

The trial is meant to treat 15 patients through a maximum of 40 injections. Today's news comes a month after Neuralstem announced Emory University, which is also taking part in the Phase II trial, had treated its first trial patient.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs